Oncolytic Newcastle Disease Virus Co-Delivered with Modified PLGA Nanoparticles Encapsulating Temozolomide against Glioblastoma Cells: Developing an Effective Treatment Strategy
/in Glioblastoma, International Publications, Newcastle Disease VirusPosterpräsentation auf der Jahrestagung der Association for Cancer Immunotherapy
/in Glioblastoma, International Publications, IOZK bei Fachtagungen, IOZK VeröffentlichungenA comprehensive update to Dendritic Cell therapy for glioma: a systematic review and meta-analysis
/in Dendritic Cells, Glioblastoma, International PublicationsSynergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusDelayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis
/in Dendritic Cells, Glioblastoma, International PublicationsImmunogenic cell death and its therapeutic or prognostic potential in high-grade glioma
/in Dendritic Cells, Glioblastoma, Immunogenic Cell Death, International Publications, Newcastle Disease VirusA Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma
/in Dendritic Cells, Glioblastoma, International PublicationsDendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
/in Dendritic Cells, Glioblastoma, International PublicationsThe Efficacy of Dendritic Cell Vaccine for Newly Diagnosed Glioblastoma: A Meta-analysis of Randomized Controlled Studies
/in Dendritic Cells, Glioblastoma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer